The journal at a glance: Q4 highlights from our Editor in Chief
Here, Editor-in-Chief Michelle Itano (University of North Carolina, Chapel Hill, NC, USA) shares her final journal highlights of the year, explaining the significance and key findings of three articles published between October and December. Standardizing caloric restriction for preclinical...
Bicycle Therapeutics secures access to reprocessed uranium to develop radiopharmaceutical pipeline
Original story from Bicycle Therapeutics (Cambridge, UK). Execution of a 15-year contract, including an option to renew with UK Nuclear Decommissioning Authority (Cumbria, UK) for access to up to 400 tonnes of reprocessed uranium (RepU), with the potential to deliver tens of thousands of doses...
A micron-resolution map for navigating tissue fiber networks
A new method has revolutionized our ability to map tissue fiber orientation and organization across tissues, diseases and sample preparations. An international group of researchers led by Marios Georgiadis from Stanford Medicine (CA, USA) has recently developed a simple, low-cost method for...
Breaking Down the Security, Risk of Recent University Firing
Security expert discusses the recent firing of University of Michigan coach Sherrone Moore. Continue reading →
Human Oversight Is the Missing Link in GenAI Trust
Human oversight will determine when genAI becomes enterprise-grade. Continue reading →
Nektar sees silver lining as autoimmune drug ‘narrowly’ misses in alopecia study
Despite being unable to declare statistical success, the company claimed its therapy showed enough promise to support moving into late-stage testing. Continue reading →
Inside New Orleans’ Real Time Crime Center
Director Ross Bourgeois explains how New Orleans built a 24/7 real time crime center that fuses video, CAD, LPR, and strict governance. Continue reading →
Addition emerges with $100M to make gene therapies for chronic and rare diseases
Backed by a handful of prominent investors including the Gates Foundation, the startup is pursuing an approach it believes can sidestep issues seen with traditional gene therapy technology. Continue reading →
Developing a path forward in cancer cachexia
Pfizer scientists have been working to advance understanding of – and potential treatments for – cachexia. Continue reading →